FDA grants fast review for Horizon’s rare eye disease drugThe FDA has granted a fast review for Horizon Therapeutics’ teprotumumab for active thyroid eye disease (TED), a Share XFDA grants fast review for Horizon’s rare eye disease drughttps://pharmaphorum.com/news/fda-grants-fast-review-for-horizons-rare-eye-disease-drug/
